HHLR ADVISORS, LTD.
13F Holdings and Portfolio Analysis
Zhang Lei 2019 Q1 13F holdings, quarterly changes, portfolio value trend and position weight distribution.
HHLR ADVISORS, LTD. Overview
HHLR ADVISORS, LTD. held 30 stocks in 2019 Q1, with total market value around $3.59B.
HHLR ADVISORS, LTD.'s top five holdings in 2019 Q1: BeOne Medicines AG(ONC) 16.32%, JD.com, Inc.(JD) 12.63%, TAL Education Group(TAL) 11.47%, iQIYI, Inc.(IQ) 8.37%, Alibaba Group Holding Limited(BABA) 7.18%.
- Portfolio Value
- $3.59B
- Current Holdings
- 30 stocks
- New / Increased
- 5 / 9
- Reduced / Exited
- 2 / 7
Current Holdings
| 1 | BeOne Medicines AGONC | 0.59 | 16.32% | 4.44 - | $132.00 | $316.42 +139.71% | $140.26 | 0.00 | 0.50 | +$0.78B+125.60% | Held |
| 2 | JD.com, Inc.JD | 0.45 | 12.63% | 15.04 - | $30.15 | $33.07 +9.69% | $20.93 | 0.00 | 0.50 | +$0.18B+58.00% | Held |
| 3 | TAL Education GroupTAL | 0.41 | 11.47% | 11.41 +52.63% | $36.08 | $11.09 -69.26% | $29.92 | +3.93 | 0.50 | -$0.21B-62.94% | Increased |
| 4 | iQIYI, Inc.IQ | 0.30 | 8.37% | 12.56 +1008.52% | $23.92 | $2.03 -91.51% | $23.10 | +11.42 | 0.50 | -$0.26B-91.21% | Increased |
| 5 | Alibaba Group Holding LimitedBABA | 0.26 | 7.18% | 1.41 - | $182.45 | $125.39 -31.27% | $137.07 | 0.00 | 0.50 | -$0.02B-8.52% | Held |
| 6 | CHINA BIOLOGIC PRODS HLDGS ICBPO | 0.25 | 6.99% | 2.75 - | $91.25 | - | $75.91 | 0.00 | 0.50 | +$0.04B+20.21% | Held |
| 7 | Meta Platforms, Inc.META | 0.20 | 5.48% | 1.18 | $166.69 | $612.96 +267.72% | $166.69 | +1.18 | 0.25 | +$0.53B+267.72% | New |
| 8 | Mondelez International, Inc.MDLZ | 0.15 | 4.19% | 3.01 -14.59% | $49.92 | $62.41 +25.02% | $40.03 | -0.51 | 0.50 | +$0.07B+55.91% | Reduced |
| 9 | BLUEPRINT MEDICINES CORPBPMC | 0.12 | 3.34% | 1.50 +4.72% | $80.05 | - | $55.09 | +0.07 | 0.50 | +$0.04B+45.31% | Increased |
| 10 | FibroGen, Inc.FGEN | 0.11 | 3.03% | 2.00 - | $54.35 | $10.38 -80.90% | $46.28 | 0.00 | 0.50 | -$0.07B-77.57% | Held |
| 11 | Sea LimitedSE | 0.10 | 2.82% | 4.30 | $23.52 | $90.53 +284.91% | $23.52 | +4.30 | 0.25 | +$0.29B+284.91% | New |
| 12 | MELCO RESORTS AND ENTMNT LTD ADRMLCO | 0.10 | 2.77% | 4.40 +16928.36% | $22.59 | - | $22.56 | +4.37 | 0.50 | +$0.00B+0.13% | Increased |
| 13 | ENSTAR GROUP LIMITEDESGR | 0.09 | 2.63% | 0.54 | $174.00 | $22.00 -87.36% | $174.00 | +0.54 | 0.25 | -$0.08B-87.36% | New |
| 14 | PDD HOLDINGS INC COMMON STOCKPDD | 0.08 | 2.16% | 3.13 +81.04% | $24.80 | $88.14 +255.42% | $23.50 | +1.40 | 0.50 | +$0.20B+275.14% | Increased |
| 15 | Bilibili Inc.BILI | 0.07 | 1.82% | 3.45 +58.51% | $18.95 | $27.05 +42.74% | $16.20 | +1.27 | 0.50 | +$0.04B+66.98% | Increased |
| 16 | MYOKARDIA INCMYOK | 0.05 | 1.41% | 0.98 +13.71% | $51.99 | - | $49.24 | +0.12 | 0.50 | +$0.00B+5.59% | Increased |
| 17 | Apellis Pharmaceuticals, Inc.APLS | 0.05 | 1.40% | 2.58 +15.70% | $19.50 | $24.52 +25.74% | $14.05 | +0.35 | 0.50 | +$0.03B+74.57% | Increased |
| 18 | LINE CORPLN | 0.04 | 1.18% | 1.21 - | $35.21 | $21.35 -39.36% | $34.11 | 0.00 | 0.50 | -$0.02B-37.41% | Held |
| 19 | BRIGHT SCHOLAR ED HLDGS LTDBEDU | 0.04 | 1.15% | 3.99 - | $10.34 | - | $9.21 | 0.00 | 0.50 | +$0.00B+12.27% | Held |
| 20 | Kiniksa Pharmaceuticals International, plcKNSA | 0.03 | 0.92% | 1.84 +32.18% | $18.06 | $38.64 +113.95% | $25.65 | +0.45 | 0.50 | +$0.02B+50.66% | Increased |
| 21 | TENCENT MUSIC ENTMT GROUPTME | 0.03 | 0.74% | 1.47 - | $18.10 | $9.22 -49.06% | $13.22 | 0.00 | 0.50 | -$0.01B-30.26% | Held |
| 22 | Gossamer Bio, Inc.GOSS | 0.02 | 0.57% | 0.94 | $21.67 | $2.19 -89.89% | $21.67 | +0.94 | 0.25 | -$0.02B-89.89% | New |
| 23 | G1 THERAPEUTICS INCGTHX | 0.02 | 0.44% | 0.95 - | $16.60 | - | $19.15 | 0.00 | 0.50 | -$0.00B-13.32% | Held |
| 24 | Sohu.com LimitedSOHU | 0.01 | 0.37% | 0.80 - | $16.58 | $14.40 -13.15% | $17.42 | 0.00 | 0.50 | -$0.00B-17.33% | Held |
| 25 | Arvinas, Inc.ARVN | 0.01 | 0.26% | 0.63 - | $14.76 | $9.52 -35.50% | $12.85 | 0.00 | 0.50 | -$0.00B-25.91% | Held |
Showing 1-25 of 30
"Holding Period (yrs)" is the latest uninterrupted holding duration, calculated by dividing continuous reported quarters by 4.
Cost basis is an estimate and can differ materially from the actual cost, especially in edge cases.
Cost basis estimate: from the latest uninterrupted holding period, new or increased shares are added to the cost pool at the report price; reductions remove shares at the then-average cost. Example: buy 100 shares at $10 in Q1 and add 50 shares at $16 in Q2, estimated cost basis is (100 x 10 + 50 x 16) / 150 = $12 per share.
Return shows estimated dollar return on top and percentage return below. It uses current price when available, otherwise report price.
Exited Holdings
Stocks no longer disclosed in the current 13F portfolio for 2019 Q1.
| 1 | 58 COM INCWUBA | 1.48 | 0.25 | $54.21 | $54.21 | $0.00B0.00% |
| 2 | IKANG HEALTHCARE GROUP INC ADRKANG | 2.92 | 0.25 | $20.38 | $20.38 | $0.00B0.00% |
| 3 | Snap Inc.SNAP | 6.93 | 0.25 | $5.51 | $5.51 | $0.00B0.00% |
| 4 | LOXO ONCOLOGY INCLOXO | 0.13 | 0.25 | $140.07 | $140.07 | $0.00B0.00% |
| 5 | YY INCYY | 0.19 | 0.25 | $59.86 | $59.86 | $0.00B0.00% |
| 6 | PROTEOSTASIS THERAPEUTICS INPTI | 0.87 | 0.25 | $3.24 | $3.24 | $0.00B0.00% |
| 7 | NEON THERAPEUTICS INCNGTX | 0.31 | 0.25 | $5.03 | $5.03 | $0.00B0.00% |
Showing 1-7 of 7
Exited holdings are stocks disclosed in the previous report period but no longer disclosed in the current 13F portfolio.
"Holding Period (yrs)" is the latest uninterrupted holding duration, calculated by dividing continuous reported quarters by 4.
Cost basis uses the same weighted cost-pool method as current holdings. Estimated exit price uses the current report period weighted report price when available, otherwise the previous report price; it does not represent the actual sale price.
Exit return shows estimated dollar return on top and percentage return below.
Portfolio Visuals
Track portfolio value, position weights and Top 10 history.